Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC

1 Feb 2022

Abstract excerpt

BACKGROUND: Neuroendocrine prostate cancer (NEPC) is often diagnosed as a sub-type from the castration-resistant prostate cancer (CRPC) recurred from the second generation of anti-androgen treatment and is a rapidly progressive fatal disease. The molecular mechanisms underlying the trans-differentiation from CRPC to NEPC are not fully characterized, which hampers the development of effective targeted therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caveolin-1 and cellular processes
Share to Prostate Cancer Treatment and Research
Share to Sphingolipid Metabolism and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35184376
DOI: 10.1002/ctm2.695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPCPMID 35184376Read ↗

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsSemantic proximity Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapySemantic proximity Read ↗

A novel REST-regulated lncRNA PCAT-NE1 induces neuroendocrine differentiation in castration-resistant prostate cancerSemantic proximity Read ↗

Overexpression of RACGAP1 by E2F1 Promotes Neuroendocrine Differentiation of Prostate Cancer by Stabilizing EZH2 ExpressionSemantic proximity Read ↗

Molecular model for neuroendocrine prostate cancer progressionSemantic proximity Read ↗

Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancerSemantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2Semantic proximity Read ↗

INSM1 Regulates Neuroendocrine Plasticity and Tumor Progression in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.